{"id":"W4408121967","doi":"10.2340/actadv.v105.42572","title":"Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study","year":2025,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Sanofi Genzyme; LEO Pharma; Bausch Health; Novo Nordisk; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Ortho Dermatologics; Cilag; Mylan; UCB Pharma; Kongelig Hofbuntmager Aage Bangs Fond; Regeneron Pharmaceuticals; Simon Spies Fonden; Les Laboratories Pierre Fabre; Celgene; Sanofi; Pfizer; Samsung; Galápagos; National Psoriasis Foundation; Amgen","keywords":"Medicine; Biosimilar; Adalimumab; Psoriasis; Cohort; Cohort study; Drug; Family medicine; Internal medicine; Pharmacology; Dermatology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001677192,0.0003981951,0.001191239,0.0002815398,0.0003407976,0.00003104101,0.0008613645,0.000562904,0.0005408094],"category_scores_gemma":[0.0008937673,0.00030817,0.0004263653,0.0004661141,0.0002933696,0.0001060165,0.0003389136,0.0004720641,0.00001904705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008388233,"about_ca_system_score_gemma":0.0003424691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005440565,"about_ca_topic_score_gemma":0.0005341002,"domain_scores_codex":[0.9968405,0.0006791985,0.0009187044,0.0007714876,0.0002152283,0.0005748734],"domain_scores_gemma":[0.9969339,0.001786363,0.0003068117,0.0007118144,0.000173402,0.00008770925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001285539,0.001839719,0.9289453,0.0001135508,0.004158623,0.00008055983,0.0002725631,7.998486e-7,0.01489003,0.002163298,0.04371488,0.002535169],"study_design_scores_gemma":[0.01452627,0.0006256818,0.7032783,0.0005042466,0.002714876,0.00001339167,0.001511975,0.00025372,0.08882984,0.005591486,0.1808617,0.001288557],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98774,0.0007068602,0.0007365686,0.003958979,0.002634047,0.001392755,0.00018361,0.0001364307,0.002510775],"genre_scores_gemma":[0.9952306,0.0001680573,0.001368402,0.001173675,0.00007594005,0.0002339185,0.0001204431,0.00002388946,0.001605141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.225667,"threshold_uncertainty_score":0.9999371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01488718902075747,"score_gpt":0.3182873033963715,"score_spread":0.303400114375614,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}